Abstract
Introduction
This analysis examines the historical and forecast performance for Bayer
Schering in the prescription pharma sector. The profile encompasses global
company strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark Bayer Schering Pharma' s performance against key rivals in the
ethical pharmaceutical sector
- Analyse how Bayer' s acquisition of Schering AG in 2006 has notably
enhanced the company' s HealthCare division
- Assess how an increased healthcare focus and merger-related synergies will
drive an increase in operating profit at an 8.4% CAGR over 200814
| 
View Cart
